News

FDA Approves Pfizer Tukysa Combo for Metastatic Breast Cancer Maintenance

Business

FDA Approves Pfizer Tukysa Combo for Metastatic Breast Cancer Maintenance

9 sourcesUpdated Oct 8, 20261 min read

0

FDA Approves Pfizer Tukysa Combo for Metastatic Breast Cancer Maintenance — © IJR

Sponsored

The FDA on October 7, 2026 approved Pfizer's Tukysa (tucatinib) in combination with trastuzumab and pertuzumab as front-line maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer after induction therapy. Tukysa was previously authorized for late-line treatment in advanced HER2-positive breast cancer. The decision is not an approval for early-stage breast cancer. In the Phase 3 HER2CLIMB-05 trial of 654 randomized adults, the regimen reduced the risk of disease progression or death by 36%. Median progression-free survival was 24.9 months with tucatinib versus 16.3 months with placebo, with both arms also receiving trastuzumab and pertuzumab. The FDA stated that overall-survival data were not mature at analysis. Prescribing information includes a boxed warning for hepatotoxicity. Tukysa worldwide Q2 2026 revenue was $138 million versus $132 million in Q2 2025; U.S. revenue was $96 million, down 11%. Pfizer total Q2 2026 revenue was $15,034 million. Pfizer's Q3 2026 earnings report and analyst call are scheduled for November 3, 2026. No factual disputes appear among the rated outlets in the record.

Sponsored

In this story:

More on this story

Back to News

Health

FDA approves first generic twice-yearly HIV-prevention shot

FDA approved the first generic of twice-yearly HIV-prevention shot lenacapavir at about $40 a year for 120 resource-limited countries; U.S. brand lists at $28,218.

18 sources

Health

FDA grants uniQure Huntington’s gene therapy priority review

The FDA accepted uniQure’s application for priority review of its experimental Huntington’s disease gene therapy, setting a May 1, 2027, decision target and tentatively planning an advisory committee meeting. The application seeks accelerated approval based on clinical data compared with an external control; acceptance is not approval, and a confirmatory trial is planned.

67%

Right

133%

Other

6

Total sources9

Last updatedOct 8, 2026

Does this breakdown look right?

Sponsored

How it spread

Broke money.mymotherlode.com · Oct 7, 12:57 PM ETCenter within the hourRight +1h9 sources +3h on

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Where do you land?

Whose framing of this story rings truest to you?

Sponsored

How each side headlines it

Left· 0 sources

No left coverage yet — a bubble gap.

Center· 2 sources

“Pfizer Says FDA Approved Tukysa Combination for Maintenance Treatment of Metastatic Breast Cancer”

MarketScreener · Oct 7, 2026

Right· 1 source

“Pfizer’s Tukysa approved for front-line breast cancer (PFE)”

Seeking Alpha · Oct 7, 2026

Coverage

Sponsored

Comments

Ask Genius by OpenServe:

Free account · your comment posts right after signup

Sponsored

8 sources

Sponsored

Health

FDA Proposes First Formula Nutrient Update in Decades

The FDA has proposed the first major update to U.S. infant-formula nutrition standards in nearly 30 years, revising requirements for vitamins A and D, iodine and manganese while seeking input on whether to require ingredients such as DHA, ARA and L-carnitine. The proposal also includes labeling changes; the agency said most tested formula samples had low or undetectable chemical contaminants and plans further reviews before issuing a final rule.

22 sources